BiotechTube
Aurion Biotech

Aurion Biotech

Seattle, WA; Cambridge, MA, United States· Est.

Aurion Biotech is a clinical and commercial-stage biotech focused on eliminating blindness through regenerative cell therapies for ophthalmic diseases. The company's core platform, Corneal Endothelial Cell Therapy (CECT), uses cultivated human donor cells to restore vision, with its lead candidate AURN001 advancing toward a U.S. Phase 3 trial in 2026 and its first product, Vyznova, already approved and sold in Japan. With prestigious designations from the FDA, a strategic majority investment from Alcon, and a leadership team rich in ophthalmology and cell therapy expertise, Aurion is positioned to address a significant global unmet need for millions of patients suffering from corneal endothelial disease.

aurionbiotech.com

Private Company

Total funding raised: $505M

AI Company Overview

Aurion Biotech is a clinical and commercial-stage biotech focused on eliminating blindness through regenerative cell therapies for ophthalmic diseases. The company's core platform, Corneal Endothelial Cell Therapy (CECT), uses cultivated human donor cells to restore vision, with its lead candidate AURN001 advancing toward a U.S. Phase 3 trial in 2026 and its first product, Vyznova, already approved and sold in Japan. With prestigious designations from the FDA, a strategic majority investment from Alcon, and a leadership team rich in ophthalmology and cell therapy expertise, Aurion is positioned to address a significant global unmet need for millions of patients suffering from corneal endothelial disease.

OphthalmologyRegenerative Medicine

Technology Platform

Corneal Endothelial Cell Therapy (CECT): A regenerative medicine platform using cultivated, natural, unmodified human donor corneal endothelial cells, delivered with a transient rho-kinase inhibitor, to repopulate and restore a damaged corneal endothelium without artificial scaffolds or genetic reprogramming.

Funding History

3
Total raised:$505M
Series B$265M
Series A$120M
Series A$120M

Opportunities

The primary opportunity is addressing the massive global unmet need for corneal endothelial disease with a scalable, minimally invasive cell therapy that can treat hundreds of patients from a single donor.
Further opportunities include geographic expansion beyond Japan and the U.S., developing next-generation cryopreserved formulations for easier distribution, and potentially applying the CECT platform to other ophthalmic indications.

Risk Factors

Key risks include clinical trial failure or setbacks in the pivotal Phase 3 program for AURN001, challenges in achieving market adoption and surgeon training for a novel cell injection procedure, complexities in scaling manufacturing for a global cell therapy, and potential future competition from other regenerative or surgical approaches.

Competitive Landscape

Aurion's main competitors are traditional corneal transplant surgeries (DMEK/DSAEK), which are donor-limited and surgically complex. In the cell therapy space, Aurion is a leader with an approved product in Japan and advanced clinical programs. Its differentiation lies in its use of natural cells (not reprogrammed), a decade of clinical data, strong FDA designations, and the strategic commercial partnership with Alcon, a global eye care leader.

More companies in Cell & Gene Therapy →More companies in United States →